Biodexa Pharmaceuticals (BDRX) Depreciation & Amortization (CF) (2019 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Depreciation & Amortization (CF) of $86148.1 for Q3 2021, down 26.7% sequentially from $117520.1 in Q4 2020, and down 23.13% YoY from $112076.0 in Q3 2020.
Biodexa Pharmaceuticals (BDRX) Depreciation & Amortization (CF) (2019 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Depreciation & Amortization (CF) for 3 years, with the latest figure at $86148.1 in Q3 2021.
- Quarterly Depreciation & Amortization (CF) fell 23.13% year-over-year to $86148.1 in Q3 2021, while the trailing twelve-month figure through Sep 2022 was $86148.1 (down 72.72% YoY) and the FY2025 annual result came in at $179317.4, up 3.49% from the prior year.
- Depreciation & Amortization (CF) fell to $86148.1 in Q3 2021 per BDRX's latest filing, from $117520.1 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $158144.2 in Q4 2019 and troughed at $86148.1 in Q3 2021.
- A 3-year average of $118472.1 and a median of $114798.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2020 and 2021: Depreciation & Amortization (CF) retreated 25.69% in 2020, then dropped 23.13% in 2021.
- Over 3 years, Depreciation & Amortization (CF) stood at $158144.2 in 2019, then declined by 25.69% to $117520.1 in 2020, then slipped by 26.7% to $86148.1 in 2021.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $86148.1, $117520.1, and $112076.0 for Q3 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 112,601.12 |
| Dec 31, 2022 | 112,601.12 |
| Sep 17, 2021 | 86,148.06 |
| Sep 17, 2021 | 86,148.06 |
| Dec 31, 2020 | 117,520.14 |
| Dec 31, 2020 | 117,520.14 |
| Sep 10, 2020 | 112,075.95 |
| Sep 10, 2020 | 112,075.95 |
| Dec 31, 2019 | 158,144.16 |
| Dec 31, 2019 | 158,144.16 |